0001354457-24-000378.txt : 20240603
0001354457-24-000378.hdr.sgml : 20240603
20240603154022
ACCESSION NUMBER: 0001354457-24-000378
CONFORMED SUBMISSION TYPE: 25-NSE
CONFIRMING COPY:
PUBLIC DOCUMENT COUNT: 2
FILED AS OF DATE: 20240603
DATE AS OF CHANGE: 20240603
SUBJECT COMPANY:
COMPANY DATA:
COMPANY CONFORMED NAME: AGILE THERAPEUTICS INC
CENTRAL INDEX KEY: 0001261249
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
ORGANIZATION NAME: 03 Life Sciences
IRS NUMBER: 000000000
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
FILING VALUES:
FORM TYPE: 25-NSE
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-36464
BUSINESS ADDRESS:
STREET 1: 500 COLLEGE ROAD EAST
STREET 2: SUITE 310
CITY: PRINCETON
STATE: NJ
ZIP: 08540-6635
BUSINESS PHONE: 609-683-1880
MAIL ADDRESS:
STREET 1: 500 COLLEGE ROAD EAST
STREET 2: SUITE 310
CITY: PRINCETON
STATE: NJ
ZIP: 08540-6635
FILED BY:
COMPANY DATA:
COMPANY CONFORMED NAME: Nasdaq Stock Market LLC
CENTRAL INDEX KEY: 0001354457
ORGANIZATION NAME:
IRS NUMBER: 521165937
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
FILING VALUES:
FORM TYPE: 25-NSE
BUSINESS ADDRESS:
STREET 1: One Liberty Plaza
CITY: New York
STATE: NY
ZIP: 10006
BUSINESS PHONE: 301-978-4144
MAIL ADDRESS:
STREET 1: Office of General Counsel
STREET 2: 805 King Farm Blvd.
CITY: ROCKVILLE
STATE: MD
ZIP: 20850
FORMER COMPANY:
FORMER CONFORMED NAME: The Nasdaq Stock Market LLC
DATE OF NAME CHANGE: 20060224
25-NSE
1
primary_doc.xml
X0203
0001354457
Nasdaq Stock Market LLC
0001261249
AGILE THERAPEUTICS INC
001-36464
101 Poor Farm Road
Princeton
NJ
NEW JERSEY
08540
609-683-1880
Common stock
17 CFR 240.12d2-2(b)
Aravind Menon
Hearings Advisor
2024-06-03
EX-99.25
2
agrxdelistreason.txt
Delisting Determination, The Nasdaq Stock Market, LLC, June 3, 2024,
Agile Therapeutics, Inc.
The Nasdaq Stock Market LLC (the Exchange) has determined to remove
from listing the securities of Agile Therapeutics, Inc., effective
at the opening of the trading session on June 13, 2024.
Based on review of information provided by the Company, Nasdaq Staff
determined that the Company no longer qualified for listing on the
Exchange pursuant to Listing Rule 5550(b)(1).
The Company was notified of the Staff determination on September 27,
2023. On October 4, 2023, the Company exercised its right to appeal
the Staff determination to the Listing Qualifications Hearings Panel
(Panel) pursuant to Listing Rule 5815.
On December 4, 2023, upon review of the information provided by the
Company, the Panel determined to grant the Company request to remain
listed in the Exchange subject to a series of milestones (the Decision).
On February 13, 2024, in response to a request by the Company, the
Panel amended the terms of the Decision.
On March 22, 2024, based on the Company failure to meet the terms
of the amended Decision, the Panel determined to delist the Company.
The Company securities were suspended on March 26, 2024.
The Company did not appeal the delist decision to the Nasdaq Listing
and Hearing Review Council (Council) and the Council did not call
the matter for review. The Staff determination to delist the Company
became final on May 6, 2024.